Sep 6, 2021
Philogen S.p.A., a clinical-stage biotechnology company focused on antibody- and small molecule-based targeted therapeutics, will announce its Interim Results for the six months ended 30th June 2021 following a Board of Director's meeting to be held on Tuesday 28th September 2021.
Prof. Dr. Dario Neri, Chief Executive Officer, Dr. Laura Baldi, Chief Financial Officer, Dr. Christian Lizak, and Dr. Emanuele Puca will host a virtual briefing for sell-side analysts at 12:00 ET / 17:00 BST / 18:00 CEST on September 29, 2021.
For more details or to attend the virtual briefing, please contact [email protected].
About Philogen
Philogen is a Swiss-Italian, fully integrated, biotech company engaged in the discovery and development of novel pharmaceutical and biopharmaceutical products. Philogen's strategy is to deliver bioactive agents, for example cytokines or drugs, to the site of disease using antibodies and small organic ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and preclinical candidates in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem in Zürich, Switzerland. Philogen is listed on the Italian stock exchange and has signed agreements with several major pharmaceutical companies. For more information please visit www.philogen.com and www.philochem.com.
For more information please contact:
Philogen
Dr. Christian Lizak (Business Development) / Dr. Emanuele Puca (Investor Relations)
+41 (0) 43 544 88 00
[email protected] / [email protected]
Consilium Strategic Communications
Mary-Jane Elliott, Davide Salvi
Fewer orders and higher costs are squeezing restaurants big and small as people on the weight-loss drugs eat and drink less when dining out.
The fiscal 2026 earnings cycle has underscored the extraordinary momentum behind the AI boom, with tech giants posting record revenues while their shares have also rallied. But beneath the headline numbers, a new test is emerging: how long can AI-driven cash generation keep pace with the massive investment required to expand computing capacity?
The president, who had hoped to tout a growing economy on the campaign trail, has found it hard to break through as workers’ wages fail to keep up.
Immediate action is needed to help households struggling with bills this winter, says trade body Energy UK.
Cheap labor and global supply chains are among the obstacles to President Trump’s plan to bring generic drug manufacturing back home.
The facility offers essential items for free, including clothes for babies and small children.
Households across Northern Ireland face increasing pressure on the cost of living as energy price hikes have come into effect.
The co-ordinated release is aimed at heading off further price spikes and avoiding a ban on US diesel exports.
The Trump administration again defended the decision to bar CNN, MS NOW and Politico from the White House and to exclude journalists from the pool that covers the president in small spaces.
The inquiry by the Commodity Futures Trading Commission centers on bets the former congressman made on Kalshi in the weeks before he was pardoned in January 2025.
The move followed reports detailing how A7, a Moscow firm, uses shell companies around the world to move funds for clients who are themselves subject to sanctions.
G20 trade ministers meet in Wisconsin amid trade tensions
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.